Actively Recruiting
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Led by West China Hospital · Updated on 2024-08-09
10
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.
CONDITIONS
Official Title
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed diagnosis of colorectal cancer
- Karnofsky performance status of 0-1
- Tumors identified as pMMR by immunohistochemistry or MSS/MSI-L by genetic testing
- Stage IV disease diagnosed by imaging with complete resection of primary and metastatic tumors and no evidence of disease after surgery
- High risk of recurrence such as liver metastasis CRS score greater than 3 or successful conversion therapy
- Multiple peritoneal metastases after CC0
- Normal function of main organs
- Patient has provided written informed consent
You will not qualify if you...
- Tumor emergencies
- Abnormal coagulation function
- Contagious diseases such as HIV, HBV, or HCV infection
- Mental disorders
- Presence of other concurrent tumors
- Immunological co-morbidities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Colorectal Cancer Center, West China Hospital
Chengdu, Chengdu/Sichuan, China, 610000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here